

## INTRODUCTION

This IRB approved study was to observe the therapeutic effect of ultra-low-dose bremsstrahlung radiation produce by 32P source on autism spectrum disorder.

## Methods

31 children diagnosed with autism based on DSM-5 criteri were selected (26 boys and 5 girls, mean age of 7, range 4 16y). A 1.85 MBq solution of P32 was diluted evenly dripp onto a filter paper to create a uniform radioactive source, covered with a 0.03 mm thick lead foil on the surface, and sealed in a plastic bag to generate an applicator treatmen source. The P32 bremsstrahlung dose rate was  $1^{2} \times 10-6$ SV/h, measured with a Automess 6150AD-6/H radiation detector. The applicator with the lead foil side was placed respectively on the forehead, bilateral temporal tops, and occipital region. A treatment course consists of twenty day The initial treatment lasted one hour, and subsequent treatment times were adjusted according to the Phosphor 32 decay factor.

All children were assessed using the Childhood Autism Rat Scale (CARS) and Autism Behavior Checklist (ABC), before treatment, and three-month after. Among them, five children underwent PET-MR fluorodeoxyglucose-18 (FDG) brain metabolic imaging before and three months after treatment. Images was processed using SPM12 software. Wilcoxon signed tank sum test was used to compare the scores pre/post treatment.

This is the first study reporting the ground breaking and encouraging therapeutic effect of ultra-low-dose P32 bremsstrahlung radiation on treating children with autism. Extensive further research is warranted to explore the mechanism of action and best clinical practices.

# Treatment of Autism Spectrum Disorder (ASD) with Ultra Low Dose Bremsstrahlung Radiation (ULDBR) produced by Phosphorus-32: Initial Clinical Observations

Haitao Hao<sup>1,2</sup>, Jun Yang<sup>1,2</sup>, Shaowei Jia<sup>3</sup>, Baoci Shan<sup>4</sup>, Guangjuan Mao<sup>4</sup>, Yun Zhang<sup>5</sup>, Fengge Zhang<sup>12</sup>, Weisong Yu<sup>6</sup>, Jiaqiang Qian<sup>2</sup>, Xiaohui Jiang<sup>1</sup> 1, Junxin Oncology Group 2, Quanzhou Binhai Hospital, 3Beijing university Shenzhen hospital, 4Institute of High Energy Physics, Chinese Academy of Sciences, 5 Xiang'an Hospital of XiaMen University, 6University of Health and Rehabilitation Sciences

	Result
ed	27 (87%) out of 31 subjects had improved CARS scores. The average CARS scores significantly decreased from 59.8 (SD 24.0) pre-treatment to 42.7 (SD 24.3) post-treatment
ria 1- bed d t 5	(p < 0.001). 24(77%) subjects had improved ABC scores. The average ABC scores significantly decreased from 41.0(SD 15.9) pre-treatment to 31.5 (SD 9.2) post-treatment $(p < 0.001)$ . Eight subjects did not improve on either ABC or CARS score, including three subjects did not improve on both scores. Out of the eight cases, seven exhibited cognitive improvements, such as enhanced eye contact, responsiveness, and language comprehension. The 8th child showed significant emotional stability, no longer having tantrums without cause, and experienced noticeable improvements in sleep disorders.
iys. rus-	The comparison of PET/MR brain 18F-FDG metabolic imaging before and after treatment in the five cases shows that there were significant changes in metabolism and volume of certain brain regions after treatment, suggesting qualitative changes in brain function and even structure following the treatment.
)	During the treatment, some children experienced 3-7 days of abnormal excitement and reduced sleep duration. No other significant side effects were observed during treatment and a three-month follow-up showed no regression. These children's growth and development appeared to be normal.

### CONCLUSION

ID	Sex	Age	ABC Score (Prior)	ABC Score (After)	ABC Score (Prior)	ABC Score (After)
1	Μ	4.2	46	31	38	33
2	F	5	89	68	38	32
3	Μ	5	51	38	36	35
4	Μ	8	78	30	74	26
5	F	5	104	16	39	26
6	Μ	11	89	35	52	25
7	Μ	8	38	24	77	40
8	Μ	9	48	30	36	29
9	Μ	10	43	40	79	52
10	Μ	8	23	0	28	12
11	Μ	3	27	14	24	18
12	Μ	11	75	76	40	40
13	Μ	7	39	27	82	45
14	Μ	5.7	35	28	39	31
15	Μ	9.2	36	7	25	7
16	F	4.5	98	36	45	30
17	F	6	69	51	34	34
18	Μ	5.2	90	91	47	35
19	Μ	6	95	85	46	40
20	Μ	6	58	50	35	34
21	Μ	3.9	84	69	38	35
22	Μ	3.8	53	44	31	29
23	Μ	5	97	87	36	41
24	Μ	6	59	78	30	32
25	Μ	9	36	7	25	19
26	F	5	32	29	30	24
27	Μ	14	43	40	31	30
28	М	5	43	53	31	35
29	М	16	46	40	28	30
30	М	5.6	64	43	37	36
31	Μ	8	67	57	40	40
		7.0	59.84	42.71	41.00	31.45

## **CASE STUDY:** 4y old Girl behavior and imaging findings

#### •Before Treatment:

- Unable to speak, no eye contact, gaze was blank.
- Unable to understand instructions, enjoyed spinning and was hyperactive
- No sense of danger, no emotional attachment, no interaction with others, and did not play with peers.

#### •After Treatment:

- Eyes became lively, able to make eye contact.
- Learned simple words (e.g., "go out," "sleep"), could say "Dad," "Mom," and "sister."
- Learned to ride a bicycle, could understand more instructions.
- Developed attachment to her mother and began interacting with other children.
- Learned to draw and build blocks by observing her sister.

#### **PET-MRI Imaging Findings:**

#### •Before Treatment:

- Reduced cerebral cortical metabolism (red arrow).
- Abnormally increased metabolism in the occipital lobe (green arrow).

#### •After Treatment:

- Significant improvement in cerebral cortical metabolism (yellow arrow).
- Marked reduction in occipital lobe metabolism (blue arrow).
- Abnormal hypermetabolism in Brodmann areas 9, 10, 17, 18, and 19 significantly decreased.
- Metabolism in the frontal, parietal, temporal lobes, and basal ganglia improved significantly, particularly in Broca's area.



